Otsuka Pharmaceutical Development & Commercialization, Inc.
This Phase 3 study will evaluate the safety, effectiveness, tolerability, and how the body processes JNT-517 in children, adolescents, and adults with phenylketonuria. Participants will be randomly assigned to receive either JNT-517 or placebo during an initial 6-week treatment period. After this period, eligible participants will receive JNT-517 for an additional 46 weeks.
Inclusion Criteria: 1. Male or female participants aged 4 years or older. 2. Diagnosed with phenylketonuria. 3. Have phenylalanine levels that meet study requirements. 4. Meet study-specific requirements regarding current treatment for phenylketonuria. 5. Willing and able to follow study dietary requirements. 6. Weigh at least 12.5 kilograms. 7. If able to become pregnant or father a child, willing to follow the study's contraception requirements. 8. Any ongoing mental health condition must be stable before entering the study. 9. Able to provide informed consent (or have consent provided by a…
JNT-517 orally
JNT-517 matching placebo orally